Stockpolly
Search
CLYM · NASDAQ · Biotechnology

Climb Bio (CLYM)

Develops antibody programs for immune-mediated diseases.

$15.11
Pre-market+0.07 (+0.43%)
At close$15.04(+1.48%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
553561211231115191515
Research & development3315366177914910
222455646666
General & administrative222455646006
Other expenses000000000000
Operating income−5−5−3−56−12−11−23−11−15−19−15−15
111132222212
Interest income111003220202
Other non-operating income0−1−1−1−3−2−2−2−2−2−10
Income before tax−4−4−2−55−9−8−21−9−13−18−14−13
Net income from continuing operations−4−4−2−55−9−8−21−9−13−18−14−13
Net income−4−4−2−55−9−8−21−9−13−18−14−13
EPS, basic−$0.15−$0.13−$0.06−$1.81−$0.13−$0.13−$0.31−$0.13−$0.19−$0.26−$0.20−$0.18
EPS, diluted−$0.15−$0.13−$0.06−$1.81−$0.13−$0.13−$0.31−$0.13−$0.19−$0.26−$0.20−$0.18
Weighted average shares, basic272728306765676868676876
Weighted average shares, diluted272728306765676868676876
EBITDA−5−4−2−55−9−8−21−9−13−17−14−15
Depreciation & amortization000000000000
EBIT−5−4−2−55−9−8−21−9−13−18−14−15